Aumento do risco de mortalidade por COVID-19 em pessoas com obesidade
DOI:
https://doi.org/10.15253/2175-6783.20232481453Palavras-chave:
COVID-19; Obesidade; Mortalidade; Fatores de Risco.Resumo
Objetivo: analisar o risco de mortalidade por COVID-19 em pessoas com obesidade. Métodos: estudo observacional, retrospectivo e analítico. Os dados foram coletados no Sistema Estadual de Análise de Dados. Para a análise comparativa de pessoas com e sem obesidade, adotou-se n=168.808. As análises foram realizadas por meio do modelo de regressão log-binomial e cálculo de risco relativo. O modelo comparativo foi ajustado ao sexo, faixa etária, cardiopatia e diabetes. Resultados: em mais de 95% das notificações de COVID-19, a informação quanto ao fator de risco obesidade foi registrada como ignorado. Pessoas obesas com COVID-19 apresentaram 26% maior risco de óbito quando comparadas às pessoas sem obesidade. Indivíduos obesos nas faixas etárias entre 11 a 60 anos apresentaram os maiores riscos de mortalidade comparados aos indivíduos sem obesidade. As mulheres obesas nas faixas etárias de 31 a 50 anos e idosas acima de 71 anos apresentaram menor risco de mortalidade quando comparadas aos homens obesos. Conclusão: pessoas obesas, principalmente os adultos, possuem risco aumentado de mortalidade por COVID-19. Contribuições para a prática: auxiliar o estabelecimento de estratégias de saúde pública que atuem na identificação dos perfis dos indivíduos considerados de alto risco na pandemia ocasionada pelo vírus SARS-CoV-2.
Referências
Yoon J. Prevalence of obesity and incidence of obesity-related comorbidities in Koreans based on national health insurance service health checkup data 2006-2015. J Obes Metab Syndr 2018;27:46-52. doi: https://dx.doi.org/10.7570/jomes.2018.27.3.195
Instituto Brasileiro de Geografia e Estatística (IBGE). Pesquisa Nacional de Saúde 2019: atenção primária à saúde e informações antropométricas [Internet]. 2020 [cited Aug 29, 2022]. Available from: https://biblioteca.ibge.gov.br/visualizacao/livros/liv101758.pdf
Bliss ES, Whiteside E. The gut-brain axis, the human gut microbiota and their integration in the development of obesity. Front Physiol. 2018;9:900. doi: https://doi.org/10.3389/fphys.2018.00900
Nogueira-de-Almeida CA, Del Ciampo LA, Ferraz IS, Del Ciampo IRL, Contini AA, Ued FDV. COVID-19 and obesity in childhood and adolescence: a clinical review. J Pediatr (Rio J). 2020;96(5):546-8. doi: https://doi.org/10.1016/j.jped.2020.07.001
Poly TN, Islam MM, Yang HC, Lin MC, Jian WS, Hsu MH, et al. Obesity and mortality among patients diagnosed with COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2021;8:620044. doi: https://dx.doi.org/10.3389/fmed.2021.62004
Yang J, Hu J, Zhu C. Obesity aggravates COVID-19: a systematic review and meta-analysis. J Med Virol. 2021;93(1):257-61. doi: https://doi.org/10.1002/jmv.26237
Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020;28(7):1195-9. doi: http://doi.org/10.1002/oby.22831
Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis. 2020;71(15):896-7. doi: https://doi.org/10.1093/cid/ciaa415
Souza FSH, Hojo-Souza NS, Batista BDO, Silva CM, Guidoni DL. On the analysis of mortality risk factors for hospitalized COVID-19 patients: a data-driven study using the major Brazilian database. PLoS One. 2021;16(3):e0248580. doi: https://doi.org/10.1371/journal.pone.0248580
Fundação Sistema Estadual de Análise de Dados - SEADE. Boletim completo [Internet]. 2022 [ci- ted Apr 11, 2022]. Available from: https://www.seade.gov.br/coronavirus/#
Instituto Brasileiro de Geografia e Estatística (IBGE). População [Internet]. 2021 [cited Apr 2, 2022]. Available from: https://cidades.ibge.gov.br/brasil/sp/panorama
Cai Q, Chen F, Wang T, Luo F, Liu X, Wu Q, et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care. 2020;43(7):1392-8. doi: https://doi.org/10.2337/dc20-0576
Du Y, Lv Y, Zha W, Zhou N, Hong X. Association of body mass index (BMI) with critical COVID-19 and in-hospital mortality: a dose-response meta-analysis. Metabolism. 2021;117:154373. doi: https://doi.org/10.1016/j.metabol.2020.154373
Yu W, Rohli KE, Yang S, Jia P. Impact of obesity on COVID-19 patients. J Diabetes Complications. 2021;35(3):107817. doi: http://dx.doi.org/10.1016/j.jdiacomp.2020.107817
Kim J, Nam JH. Insight into the relationship between obesity-induced low-level chronic inflammation and COVID-19 infection. Int J Obes. 2020;44:1541-2. doi: https://dx.doi.org/10.1038/s41366-020-0602-y
Albashir AAD. The potential impacts of obesity on COVID-19. Clin Med (Lond). 2020;20(4): e109-e113. doi: https://dx.doi.org/10.7861/clinmed.2020-0239
Cheng WA, Turner L, Marentes Ruiz CJ, Tanaka ML, Congrave-Wilson Z, Lee Y, et al. Clinical manifestations of COVID-19 differ by age and obesity status. Influenza Other Respir Viruses. 2022;16(2):255-64. doi: https://doi.org/10.1111/irv.12918
Emilsson V, Gudmundsson EF, Aspelund T, Jonsson BG, Gudjonsson A, Launer LJ, et al. Serum levels of ACE2 are higher in patients with obesity and diabetes. Obes Sci Pract. 2020;7(2):239-43. doi: https://doi.org/10.1002/osp4.472
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. China medical treatment expert group for covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. doi: http://doi.org/10.1056/NEJMoa2002032
Abdolmaleki G, Taheri MA, Paridehpour S, Mohammadi NM, Tabatabaei YA, Mousavi T, et al. A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines. Daru J Pharm Sci. 2022;1-28. doi: https://doi.org/10.1007/s40199-022-00446-8
Nakeshbandi M, Maini R, Daniel P, Rosengarten S, Parmar P, Wilson C, et al. The impact of obesity on COVID-19 complications: a retrospective cohort study. Int J Obes (Lond). 2020;44(9):1832-7. doi: https://doi.org/10.1038/s41366-020-0648-x
Brandi ML. Are sex hormones promising candidates to explain sex disparities in the COVID-19 pandemic? Rev Endocr Metab Disord. 2022;23(2):171-83. https://dx.doi.org/10.1007/s11154-021-09692-8
Schurz H, Salie M, Tromp G, Hoal EG, Kinnear CJ, Möller M. The X chromosome and sex-specific effects in infectious disease susceptibility. Hum Genomics. 2019;13(1):2. https://doi.org/10.1186/s40246-018-0185-z
Shepherd R, Cheung AS, Pang K, Saffery R, Novakovic B. Sexual dimorphism in innate immunity: the role of sex hormones and epigenetics. Front Immunol. 2021;11:604000. doi: https://doi.org/10.3389/fimmu.2020.604000
Ding T, Zhang J, Wang T, Cui P, Chen Z, Jiang J, et al. Potential influence of menstrual status and sex hormones on female severe acute respiratory syndrome coronavirus 2 infection: a cross-sectional multicenter study in Wuhan, China. Clin Infect Dis. 2021;72(9):e240-e248. doi: https://doi.org/10.1093/cid/ciaa1022
Halpern B, Louzada MLDC, Aschner P, Gerchman F, Brajkovich I, Faria-Neto JR, et al. Obesity and COVID-19 in Latin America: a tragedy of two pandemics-official document of the Latin American Federation of Obesity Societies. Obes Rev. 2021;22(3):e13165. doi: https://doi.org/10.1111/obr.13165
Bhaskaran K, Santos-Silva I, Leon DA, Douglas IJ, Smeeth L. Association of the BMI with overall and cause-specific mortality: a population-based cohort study of 3·6 million adults in the UK. Lancet. 2018;6(12):944-53. doi: https://dx.doi.org/10.1016/S2213-8587(18)30288-2
Al-Bari MAA, Hossain S, Zahan MK. Exploration of sex-specific and age-dependent COVID-19 fatality rate in Bangladesh population. World J Radiol. 2021;13(1):1-18. doi: https://doi.org/10.4329/wjr.v13.i1.1
Westheim AJF, Bitorina AV, Theys J, Shiri-Sverdlov R. COVID-19 infection, progression, and vaccination: focus on obesity and related metabolic disturbances. Obes Rev. 2021;22(10):e13313. doi: https://doi.org/10.1111/obr.13313
Siqueira PC, Cola JP, Comerio T, Sales CMM, Maciel EL. Herd immunity threshold for SARS-CoV-2 and vaccination effectiveness in Brazil. J Bras Pneumol. 2022;48(2):e20210401. doi: https://dx.doi.org/10.36416/1806-3756/e20210401
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2023 Rev Rene

Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.